Actemra Achieves Positive Trial Results As Giant Cell Arteritis Treatment, Receives Priority Review Designation From FDA

Actemra achieved positive results at the end of the Phase III trial, and its Supplemental Biologics License Application was accepted by the FDA. The medication is employed in treating patients who suffer from giant cell arteritis.